GeneDx Holdings Statistics
Total Valuation
GeneDx Holdings has a market cap or net worth of $2.05 billion. The enterprise value is $1.99 billion.
Important Dates
The next confirmed earnings date is Monday, May 4, 2026, after market close.
| Earnings Date | May 4, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
GeneDx Holdings has 29.29 million shares outstanding. The number of shares has increased by 6.51% in one year.
| Current Share Class | 29.29M |
| Shares Outstanding | 29.29M |
| Shares Change (YoY) | +6.51% |
| Shares Change (QoQ) | +0.88% |
| Owned by Insiders (%) | 1.71% |
| Owned by Institutions (%) | 90.07% |
| Float | 20.85M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 76.60 |
| PS Ratio | 4.78 |
| Forward PS | 3.68 |
| PB Ratio | 6.63 |
| P/TBV Ratio | 16.21 |
| P/FCF Ratio | 143.40 |
| P/OCF Ratio | 61.46 |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
The stock's EV/EBITDA ratio is 157.06, with an EV/FCF ratio of 139.33.
| EV / Earnings | n/a |
| EV / Sales | 4.65 |
| EV / EBITDA | 157.06 |
| EV / EBIT | n/a |
| EV / FCF | 139.33 |
Financial Position
The company has a current ratio of 2.46, with a Debt / Equity ratio of 0.37.
| Current Ratio | 2.46 |
| Quick Ratio | 2.26 |
| Debt / Equity | 0.37 |
| Debt / EBITDA | 5.46 |
| Debt / FCF | 7.93 |
| Interest Coverage | -4.60 |
Financial Efficiency
Return on equity (ROE) is -7.60% and return on invested capital (ROIC) is -4.67%.
| Return on Equity (ROE) | -7.60% |
| Return on Assets (ROA) | -1.55% |
| Return on Invested Capital (ROIC) | -4.67% |
| Return on Capital Employed (ROCE) | -2.81% |
| Weighted Average Cost of Capital (WACC) | 15.54% |
| Revenue Per Employee | $328,876 |
| Profits Per Employee | -$16,170 |
| Employee Count | 1,300 |
| Asset Turnover | 0.91 |
| Inventory Turnover | 10.52 |
Taxes
| Income Tax | -116,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -23.30% in the last 52 weeks. The beta is 2.19, so GeneDx Holdings's price volatility has been higher than the market average.
| Beta (5Y) | 2.19 |
| 52-Week Price Change | -23.30% |
| 50-Day Moving Average | 75.09 |
| 200-Day Moving Average | 109.73 |
| Relative Strength Index (RSI) | 51.12 |
| Average Volume (20 Days) | 713,051 |
Short Selling Information
The latest short interest is 3.94 million, so 13.46% of the outstanding shares have been sold short.
| Short Interest | 3.94M |
| Short Previous Month | 3.86M |
| Short % of Shares Out | 13.46% |
| Short % of Float | 18.92% |
| Short Ratio (days to cover) | 4.95 |
Income Statement
In the last 12 months, GeneDx Holdings had revenue of $427.54 million and -$21.02 million in losses. Loss per share was -$0.73.
| Revenue | 427.54M |
| Gross Profit | 298.18M |
| Operating Income | -11.67M |
| Pretax Income | -21.14M |
| Net Income | -21.02M |
| EBITDA | 12.65M |
| EBIT | -11.67M |
| Loss Per Share | -$0.73 |
Full Income StatementBalance Sheet
The company has $171.28 million in cash and $113.17 million in debt, with a net cash position of $58.11 million or $1.98 per share.
| Cash & Cash Equivalents | 171.28M |
| Total Debt | 113.17M |
| Net Cash | 58.11M |
| Net Cash Per Share | $1.98 |
| Equity (Book Value) | 308.18M |
| Book Value Per Share | 10.54 |
| Working Capital | 159.38M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $33.28 million and capital expenditures -$19.02 million, giving a free cash flow of $14.26 million.
| Operating Cash Flow | 33.28M |
| Capital Expenditures | -19.02M |
| Depreciation & Amortization | 24.32M |
| Net Borrowing | -3.66M |
| Free Cash Flow | 14.26M |
| FCF Per Share | $0.49 |
Full Cash Flow StatementMargins
Gross margin is 69.74%, with operating and profit margins of -2.73% and -4.92%.
| Gross Margin | 69.74% |
| Operating Margin | -2.73% |
| Pretax Margin | -4.94% |
| Profit Margin | -4.92% |
| EBITDA Margin | 2.96% |
| EBIT Margin | -2.73% |
| FCF Margin | 3.34% |
Dividends & Yields
GeneDx Holdings does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -6.51% |
| Shareholder Yield | -6.51% |
| Earnings Yield | -1.03% |
| FCF Yield | 0.70% |
Analyst Forecast
The average price target for GeneDx Holdings is $120.71, which is 72.86% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $120.71 |
| Price Target Difference | 72.86% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (5Y) | 19.72% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on May 4, 2023. It was a reverse split with a ratio of 1:33.
| Last Split Date | May 4, 2023 |
| Split Type | Reverse |
| Split Ratio | 1:33 |
Scores
GeneDx Holdings has an Altman Z-Score of 5.64 and a Piotroski F-Score of 5.
| Altman Z-Score | 5.64 |
| Piotroski F-Score | 5 |
